Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 12/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.48 |
| ▸ | PNPLA2 | Q96AD5 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10145503 | 0.84 | FGFR3 (0.66) | FYNFGFR3DYRK3CCNT1CCNA2 | |
| SCHEMBL10145501 | 0.83 | FYN (0.48) | FYNFGFR3DYRK3CCNT1CCNA2 | |
| SCHEMBL10145525 | 0.80 | FYN (0.45) | FYNFGFR3KDRDYRK3CCNT1 | |
| SCHEMBL10145526 | 0.80 | FYN (0.44) | FYNFGFR3KDRDYRK3CCNT1 | |
| SCHEMBL10145528 | 0.79 | FGFR3 (0.45) | FYNFGFR3DYRK3CCNT1CCNA2 | |
| SCHEMBL9949705 | 0.79 | FGFR3 (0.65) | FGFR3KDR | |
| SCHEMBL10145530 | 0.77 | FGFR3 (0.46) | FYNFGFR3KDRDYRK3CCNT1 | |
| SCHEMBL10145517 | 0.77 | FGFR3 (0.57) | FGFR3KDRFGFR1 | |
| SCHEMBL10145531 | 0.77 | MAP4K1 (0.44) | FYNFGFR3KDRDYRK3CCNT1 | |
| SCHEMBL10145520 | 0.75 | FGFR3 (0.49) | FGFR3KDRDYRK1AFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2017-06-15 | — | — | US | disclosed |
| US-9533954-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2017-01-03 | — | — | US | disclosed |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754114-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FYN 53/4885FGFR3 1/4885KDR 133/4885 |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FYN 53/4885FGFR3 1/4885KDR 133/4885 |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FYN 53/4885FGFR3 1/4885KDR 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.